

Central Nervous System embryonal tumor

- Applications of Advanced Imaging for Radiotherapy Planning and Response Assessment in the Central Nervous System
 - Growth Dynamics of Brain Tumor Through the Lens of MT-Weighted MRI
 - Anatomo-functional approach to multimodal motor mapping in diffuse glioma surgery: hierarchical networks
 - An Osmosis-driven 3D-printed brain implant for drug delivery
 - Years of life lost due to central nervous system tumor subtypes in the United States
 - Tumor Microenvironment in Melanoma Brain Metastasis: A New Potential Target?
 - *PIK3CA* Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?
 - Patterns, clinical presentations, and time to diagnosis in pediatric central nervous system tumors: insights from a pediatric neuro-oncology tumor board team at a tertiary referral hospital in Ethiopia
-
-

Central Nervous System (CNS) [embryonal tumors](#) represent a heterogeneous group of highly aggressive tumors occurring preferentially in children but also described in adolescents and adults. The [World Health Organization Classification of Tumors of the Central Nervous System 2021](#), drastically changed the [diagnosis](#) of other CNS embryonal tumors including new histo-molecular tumor types.

Medulloblastoma

Medulloblastomas, molecularly defined

Medulloblastoma, WNT-activated

Medulloblastoma, SHH-activated and TP53-wildtype

Medulloblastoma, SHH-activated and TP53-mutant

Medulloblastoma non-WNT/non-SHH

Medulloblastomas, histologically defined

Other CNS [embryonal tumors](#)

Atypical teratoid/rhabdoid tumor

Cribiform neuroepithelial tumor

Embryonal tumor with multilayered rosettes

CNS neuroblastoma, FOXR2-activated

CNS tumor with BCOR internal tandem duplication

CNS embryonal tumor

Initially, the term **primitive neuroectodermal tumor (PNET)** encompassed a wide variety of previously individually named tumors which all seemed to share certain pathologic features suggesting origin from a common progenitor cell in the subependymal matrix (primitive neuroectodermal cells) (although the actual cell of origin is unknown). They are histologically indistinguishable but genetically distinct ¹⁾.

Now, the recommendation is to call these “embryonal tumors”, ²⁾ but the term PNET is entrenched. These tumors include: retinoblastoma, pineoblastoma, neuroblastoma, esthesioneuroblastoma.

Medulloblastoma (MB) is more than just a PNET of the posterior fossa, as alterations involved in evolution of MBs such as beta-catenin and APC mutations are absent in pineoblastomas and supratentorial PNETs (sPNETs). At least some MBs originate from the external granular layer (EGL) of the cerebellum.

Embryonal tumors most commonly arise in the cerebellar vermis (**medulloblastoma**), but also occur in cerebrum, pineal, brainstem or spinal cord. Primary spinal cord PNETs are extremely rare (approximately 30 cases reported by 2007 ³⁾).

Dissemination: Embryonal tumors (ETs) may disseminate via the CSF spontaneously, ⁴⁾ or iatrogenically (following surgery or shunting, the latter is a rare cause of tumor dissemination ⁵⁾). Thus, all patients with ETs require spinal axis evaluation (gadolinium enhanced MRI is about as sensitive as water-soluble myelography) and cytologic examination of CSF. Prophylactic craniospinal XRT is indicated following surgical removal, but cranial XRT is avoided if at all possible before 3 years of age to avoid intellectual impairment and growth retardation. Extraneural metastases can also occur.

Collin’s law: AKA period of recurrence (PRR) is often applied to children who have been treated for embryonal tumors (especially medulloblastoma) but may also be used with any tumor thought to arise from a gestational event. It states that PRR is equal to the age at diagnosis plus 9 months ⁶⁾. Patients that remain free of recurrence beyond the PRR have a much lower risk of recurrence, however recurrence beyond this time has been reported in a small number ($\approx 1.4\%$) of cases, ⁷⁾ and other tumors may occur e.g. as a result of induction by XRT used to treat the initial tumor.

A mass of rapidly growing cells that begins in embryonic (fetal) tissue. Embryonal tumors may be benign or malignant and include neuroblastomas and Wilms tumors. Also called embryoma.

CNS Embryonal Tumor with BRD4-LEUTX Fusion

[CNS Embryonal Tumor with BRD4-LEUTX Fusion.](#)

¹⁾

Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S,

Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature*. 2002; 415:436–442
2)

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H. WHO classification of tumors of the central nervous system. Lyon 2007
3)

Kumar R, Reddy SJ, Wani AA, Pal L. Primary spinal primitive neuroectodermal tumor: case series and review of the literature. *Pediatr Neurosurg*. 2007; 43:1–6
4)

Tomita T, McLone DG. Spontaneous Seeding of Medulloblastoma: Results of Cerebrospinal Fluid Cytology and Arachnoid Biopsy from the Cisterna Magna. *Neurosurgery*. 1983; 12:265–267
5)

Berger MS, Baumeister B, Geyer JR, Milstein J, et al. The Risks of Metastases from Shunting in Children with Primary Central Nervous System Tumors. *J Neurosurg*. 1991; 74:872–877
6)

Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. *Am J Roentgenol Radium Ther Nucl Med*. 1956; 76:988–1000
7)

Sure U, Berghorn WJ, Bertalanffy H. Collins' law. Prediction of recurrence or cure in childhood medulloblastoma? *Clin Neurol Neurosurg*. 1997; 99:113–116

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=central_nervous_system_embryonal_tumor

Last update: **2024/06/07 02:55**

